Septicemia and septic shock in pediatric patients: 140 consecutive cases on a pediatric hematology-oncology service

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 3, 1998, Pages 215-221

  Aledo, Alexander ^a   Heller, Glenn ^b   Ren, Leigh ^b   Gardner, Sharon ^c   Dunkel, Ira ^b   McKay, Shelley W ^b   Flombaum, Carlos ^b   Brown, Arthur E ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gram negative sepsis; Pediatric malignancies; Septic shock

Indexed keywords

ARTICLE; BACTEREMIA; BLOOD CULTURE; CANCER RISK; CARBON DIOXIDE TENSION; CHILDHOOD CANCER; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN CELL; INCIDENCE; MONITORING; PRIORITY JOURNAL; SEPTIC SHOCK; SEPTICEMIA;

ADOLESCENT; ADULT; BICARBONATES; CHILD; CHILD, PRESCHOOL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; LEUKOCYTE COUNT; MALE; NEOPLASMS; NEUTROPENIA; SEPSIS; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 0031815988     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199805000-00006     Document Type: Article

References (40)

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
2. Langley J, Gold R. Sepsis in febrile neutropenic children with cancer. Pediatr Infect Dis J 1988;7:34-7.
3. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
4. Brown AE. Neutropenia, fever, and infection. Am J Med 1984;76:421-8.
5. Decker MD, Edwards KM. Central venous catheter infections. Pediatr Clin North Am 1988;35:579-612.
6. Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993;119:1168-74.
7. Dawson S, Pai MKR, Smith S, et al. Right atrial catheters in children with cancer: a decade of experience in the use of tunnelled, exteriorized devices at a single institution. Am J Pediatr Hematol Oncol 1991;13:126-9.
8. Johnson PR, Decker MD, Edwards KM, et al. Frequency of Broviac catheter infections in pediatric oncology patients. J Infect Dis 1986;154:570-8.
9. Darbyshire PJ, Weightman NC, Speller DCE. Problems associated with indwelling central venous catheters. Arch Dis Child 1985;60:129-34.
10. Jacobs RF, Sowell MK, Moss MM, et al. Septic shock in children: bacterial etiologies and temporal relationships. Pediatr Infect Dis J 1990;9:196-200.
11. Jafari HS, McCracken GH Jr. Sepsis and septic shock: a review for clinicians. Pediatr Infect Dis J 1992;11:739-49.
12. Whimbey E, Kiehn TE, Brannon P, et al. Bacteremia and fungemia in patients with neoplastic disease. Am J Med 1987;82:723-30.
13. Ehni WF, Relier LB, Ellison RT III. Bacteremia in granulocytopenic patients in a tertiary-care general hospital. Rev Infect Dis 1991;13:613-9.
14. Koll BS, Brown AE. Changing patterns of infection in the immunocompromised patient with cancer. Hematol Oncol Clin North Am 1993;7:753-69.
15. Pizzo PA, Rubin M, Freifeld A, et al. The child with cancer and infection: I. empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991;119:679-94.
16. Frenck R, Kohl S, Pickering LK. Principles of total care: infections in children with cancer. In: Fernbach DJ, Vietti TJ (eds). Clinical Pediatric Oncology, 4th ed. St. Louis: Mosby Year Book, 1991:249-71.
17. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991;324:601-12.
18. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
19. Hughes WT, Pizzo PA, Wade JC, et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992;15:5206-15.
20. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990;161:397-401.
21. Johnson MP, Ramphal R. b-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990;162:981-3.
22. Bodey GP, Elting L, Kassamali H, et al. Escherichia coli bacteremia in cancer patients. Am J Med 1986;81:85-95.
23. Freifeld AG. The antimicrobial armamentarium. Hematol Oncol Clin North Am 1993;7:813-39.
24. Huijgens PC, Ossenkoppele GJ, Weijers TF, et al. Imipenem-cilastin for empirical therapy in neutropenic patients with fever: an open study with hematologic malignancies. Eur J Haematol 1991;46:42-6.
25. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytic patients. Ann Intern Med 1991;115:849-59.
26. Frieden TR, Munsiff SS, Low DE, et al. Emergence of vancomycin-resistant enterococci in New York city. Lancet 1993;342:76-9.
27. Rolston KVI, Nguyen H, Amos G, et al. A randomized double-blind trial of vancomycin versus teichoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 1994;169:350-5.
28. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989;33:791-6.
29. Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
30. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053-8.
31. Gurwith MJ, Brunton JL, Lank B, et al. Granulocytopenia in hospitalized patients: I. Prognostic factors and etiology of fever. Am J Med 1978;64:121-6.
32. Pollack MM, Fields AI, Ruttimann UE. Sequential cardiopulmonary variables of infants and children in septic shock. Clin Care Med 1984;12:554-9.
33. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-36.
34. Dofferhoff ASM, Bom VJJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
35. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-8.
36. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994;121:1-5.
37. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease: a study of 364 cases. Am J Med 1977;62:731-42.
38. Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996;77:791-8.
39. Aledo A, Gardner S, Dunkel I, et al. Incidence and outcome of septic shock in pediatric oncology patients. [Abstract 1]. Support Care Cancer 1996;4:226.
40. Kwaan HM, Weil MH. Differences in mechanism of shock caused by bacterial infections. Surg Gynecol Obstet 1969;128:37-45.